• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胸腔液标本中细胞 HE 染色涂片和配对细胞石蜡切片检测表皮生长因子受体基因。

Cell HE staining smears and paired cell paraffin sections in detection of epithelial growth factor receptor gene of pleural fluid specimens.

机构信息

Department of Pathology, Aerospace Center Hospital, Beijing 100049, China.

出版信息

Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2022 Jan 28;47(1):35-44. doi: 10.11817/j.issn.1672-7347.2022.210611.

DOI:10.11817/j.issn.1672-7347.2022.210611
PMID:35545361
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10930476/
Abstract

OBJECTIVES

The advanced non-small cell lung cancer (NSCLC) patients with pleural effusion have no opportunity for surgery treatment. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the first-line drugs for these patients with -sensitive mutation. However, the disease progression and drug update during or after treatment of EGFR-TKIs bring more challenges and puzzles to clinical diagnosis and treatment, which inevitably requires archived pleural cell samples for EGFR re-examination or comparative study. Understanding the DNA quality of archived pleural fluid samples and effectively using archival data of pleural fluid cells are of great significance for tracing the origin of cases and basic medical research. This study aims to evaluate the consistency of EGFR mutant gene expression between the 2 methods, and to explore a reliable way for preserving cytological data and making full use of cytological archival data via cell HE staining smear and cell paraffin section.

METHODS

A total of 57 pleural fluid cytology cases in the Department of Pathology of China Aerospace Center Hospital from October 2014 to April 2021 were selected. Tumor cells were detected by cell HE staining smears and immunohistochemical staining for TTF-1 and Napsin A in the paired cell paraffin sections. There were more than 200 tumor cells in cell HE staining smear and the proportion of tumor cells were ≥70% in matched cell paraffin sections. Patients with 2 cell smears (one for cell data retention and the other for DNA extraction) were selected as the research subjects, and 57 pleural fluid samples were enrolled. gene mutation was detected by amplification refractory mutation system-polymerase chain reaction in 57 paired cell HE staining smears and cell paraffin sections. DNA concentration was 2 ng/μL. Cell HE smear was amplified side-by-side with DNA samples from paired cell paraffin sections. Result determination was according to the requirements of the reagent instructions. The external control cycle threshold (Ct) value of the No. 8 well of the samples to be tested was between 13 and 21, which was considered as successful and reliable samples. When the Ct value of gene mutation was <26, it was considered as positive; when the Ct value was between 26 and 29, it was critical positive; when the Ct value was equal or more than 29, it was negative. ΔCt value was the difference between mutant Ct value and externally controlled Ct value. The smaller the ΔCt value was, the better the quality of DNA of the detected sample was.

RESULTS

Among the 57 pleural effusion samples, 42 patients were hospitalized with pleural effusion as the first symptom, accounting for 73.7% (42/57). mutation was detected in 37 samples [64.9% (37/57)]. The mutation rate for was 37.8% (14/37) while for was 48.6% (18/37). Females were 56.7% (21/37) of mutation cases. The mutation consistency rate of cell HE staining smear and matched cell paraffin sections was 100%. The ΔCt values of cell HE staining smears were less than those of matched cell paraffin sections. The mutation Ct values of 37 cytological samples were statistically analyzed according to the preservation periods of the years of 2014-2015, 2016-2017, 2018-2019, and 2020-2021. There were significant differences in cell paraffin section in the years of 2014-2015 and 2016-2017 compared with the years of 2018-2019 and 2020-2021, while no significant differences were found in cell HE staining smear. Statistical analysis of externally controlled Ct values of 57 cytological samples showed that there were significant differences between cell HE staining smears and cell paraffin section in the years of 2014-2015 and 2016-2017, compared with the years of 2018-2019 and 2020-2021. The mutational Ct values of 37 paired cell blocks and smears were all <26, and the externally controlled Ct values of 57 paired cell paraffin sections and HE staining smears were all between 13 and 21.

CONCLUSIONS

The DNA quality of cell HE smears and matched cell paraffin section met the qualified requirements. Two methods possess show an excellent consistency in detecting mutation in NSCLC pleural fluid samples. The DNA quality of cell HE staining smear is better than that of cell paraffin sections, so cell HE staining smear can be used as important supplement of the gene test source. It should be noted that the limitation of cell HE staining smears is non-reproducibility, so multiple smears of pleural fluid are recommended to be prepared for multiple tests.

摘要

目的

患有胸腔积液的晚期非小细胞肺癌(NSCLC)患者没有手术治疗的机会。表皮生长因子受体(EGFR)酪氨酸激酶抑制剂(TKI)是这些具有 - 敏感突变的患者的一线药物。然而,EGFR-TKI 治疗期间或之后的疾病进展和药物更新给临床诊断和治疗带来了更多的挑战和困惑,这不可避免地需要存档的胸腔细胞样本进行 EGFR 重新检查或比较研究。了解存档胸腔液样本的 DNA 质量,并有效地利用胸腔液细胞的存档数据,对于追踪病例的起源和基础医学研究具有重要意义。本研究旨在评估两种方法之间 EGFR 突变基因表达的一致性,并探索一种可靠的方法,通过细胞 HE 染色涂片和细胞石蜡切片保存细胞学数据并充分利用细胞学存档数据。

方法

选择 2014 年 10 月至 2021 年 4 月期间航天中心医院病理科的 57 例胸腔液细胞学病例,配对的细胞石蜡切片中用细胞 HE 染色涂片和 TTF-1、Napsin A 的免疫组织化学染色检测肿瘤细胞。细胞 HE 染色涂片中的肿瘤细胞超过 200 个,且匹配的细胞石蜡切片中肿瘤细胞的比例≥70%。选择有 2 个细胞涂片(一个用于细胞数据保留,另一个用于 DNA 提取)的患者作为研究对象,共纳入 57 例胸腔液样本。通过扩增受阻突变系统-聚合酶链反应(ARMS-PCR)在 57 个配对的细胞 HE 染色涂片和细胞石蜡切片中检测 基因突变。DNA 浓度为 2ng/μL。细胞 HE 涂片与配对细胞石蜡切片的 DNA 样本同时扩增。结果判定根据试剂说明书的要求进行。待测试样本的第 8 孔的外部对照循环阈值(Ct)值在 13 到 21 之间,被认为是成功和可靠的样本。当 基因突变的 Ct 值<26 时,被认为是阳性;当 Ct 值在 26 到 29 之间时,被认为是临界阳性;当 Ct 值等于或大于 29 时,被认为是阴性。ΔCt 值是突变 Ct 值与外部对照 Ct 值的差异。ΔCt 值越小,检测样本的 DNA 质量越好。

结果

在 57 例胸腔积液样本中,42 例患者以胸腔积液为首发症状入院,占 73.7%(42/57)。[64.9%(37/57)]共检测到 37 例样本的 突变。 突变率为 37.8%(14/37),而 突变率为 48.6%(18/37)。女性为 突变病例的 56.7%(21/37)。细胞 HE 染色涂片和匹配的细胞石蜡切片的突变一致性率为 100%。细胞 HE 染色涂片的 ΔCt 值小于匹配的细胞石蜡切片。根据 2014-2015 年、2016-2017 年、2018-2019 年和 2020-2021 年的保存年限,对 37 例细胞学样本的突变 Ct 值进行统计学分析。2014-2015 年和 2016-2017 年的细胞石蜡切片的突变 Ct 值与 2018-2019 年和 2020-2021 年相比有显著差异,而细胞 HE 染色涂片无显著差异。对 57 例细胞学样本的外部对照 Ct 值进行统计学分析,结果显示 2014-2015 年和 2016-2017 年的细胞 HE 染色涂片和细胞石蜡切片与 2018-2019 年和 2020-2021 年相比有显著差异。37 对配对的细胞块和涂片的突变 Ct 值均<26,57 对配对的细胞石蜡切片和 HE 染色涂片的外部对照 Ct 值均在 13 到 21 之间。

结论

细胞 HE 染色涂片和匹配的细胞石蜡切片的 DNA 质量符合合格要求。两种方法在检测 NSCLC 胸腔积液样本中的 突变时表现出极好的一致性。细胞 HE 染色涂片的 DNA 质量优于细胞石蜡切片,因此细胞 HE 染色涂片可以作为基因检测来源的重要补充。值得注意的是,细胞 HE 染色涂片的局限性在于不可重复性,因此建议制备多个胸腔液涂片进行多次检测。

相似文献

1
Cell HE staining smears and paired cell paraffin sections in detection of epithelial growth factor receptor gene of pleural fluid specimens.胸腔液标本中细胞 HE 染色涂片和配对细胞石蜡切片检测表皮生长因子受体基因。
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2022 Jan 28;47(1):35-44. doi: 10.11817/j.issn.1672-7347.2022.210611.
2
[Results of EGFR Mutations Detected in Pleural Effusion and Its 
Clinical Significance in 132 Patients with Advanced Non-small Cell Lung Cancer: 
A Retrospective Study in A Single Center].[132例晚期非小细胞肺癌患者胸腔积液中表皮生长因子受体突变检测结果及其临床意义:单中心回顾性研究]
Zhongguo Fei Ai Za Zhi. 2020 Dec 20;23(12):1059-1065. doi: 10.3779/j.issn.1009-3419.2020.104.23.
3
Assessment of epidermal growth factor receptor and K-ras mutation status in cytological stained smears of non-small cell lung cancer patients: correlation with clinical outcomes.评估非小细胞肺癌患者细胞学染色涂片的表皮生长因子受体和 K-ras 突变状态:与临床结局的相关性。
Oncologist. 2011;16(6):877-85. doi: 10.1634/theoncologist.2010-0155. Epub 2011 May 14.
4
Comparison of Confirmed Cytology Smears and Cell Blocks for Epidermal Growth Factor Receptor Mutation Testing in Non-Small Cell Lung Cancer.非小细胞肺癌中用于表皮生长因子受体突变检测的确诊细胞学涂片与细胞块的比较
Appl Immunohistochem Mol Morphol. 2023;31(10):701-706. doi: 10.1097/PAI.0000000000001166. Epub 2023 Oct 9.
5
Detection of epidermal growth factor receptor mutation in non-small-cell lung carcinoma using cytological and histological specimens.利用细胞学和组织学标本检测非小细胞肺癌中的表皮生长因子受体突变
J BUON. 2015 Jan-Feb;20(1):142-5.
6
Clinical value of the detection of gene mutations in pleural effusion cell blocks among patients with non-small-cell lung cancer.检测非小细胞肺癌患者胸腔积液细胞块中基因突变的临床价值。
Indian J Pathol Microbiol. 2021 Jan-Mar;64(1):107-110. doi: 10.4103/IJPM.IJPM_360_20.
7
[Analysis of the Relationship Between the Quality of Small Biopsy Specimens of 
Non-small Cell Lung Cancer and the Mutation Rate of EGFR Gene].[非小细胞肺癌小活检标本质量与表皮生长因子受体(EGFR)基因突变率的关系分析]
Zhongguo Fei Ai Za Zhi. 2021 May 20;24(5):331-337. doi: 10.3779/j.issn.1009-3419.2021.102.16.
8
Cytological-negative pleural effusion can be an alternative liquid biopsy media for detection of EGFR mutation in NSCLC patients.细胞学阴性胸腔积液可作为 NSCLC 患者 EGFR 突变检测的替代液体活检标本。
Lung Cancer. 2019 Oct;136:23-29. doi: 10.1016/j.lungcan.2019.08.004. Epub 2019 Aug 5.
9
Predicting outcomes of EGFR-targeted therapy in non-small cell lung cancer patients using pleural effusions samples and peptide nucleic acid probe assay.利用胸腔积液样本和肽核酸探针检测法预测非小细胞肺癌患者表皮生长因子受体靶向治疗的疗效
Clin Chem Lab Med. 2017 Oct 26;55(12):1979-1986. doi: 10.1515/cclm-2016-0809.
10
Comparison of the SuperARMS and ARMS for detecting EGFR mutations in liquid-based cytology specimens from NSCLC patients.比较 SuperARMS 和 ARMS 在检测非小细胞肺癌患者液体细胞学标本中 EGFR 突变中的应用。
Diagn Pathol. 2020 Jan 31;15(1):9. doi: 10.1186/s13000-019-0910-5.

引用本文的文献

1
Detection of PD‑L1 expression and epithelial‑mesenchymal transition of circulating tumor cells in non‑small cell lung cancer.非小细胞肺癌中循环肿瘤细胞的PD-L1表达及上皮-间质转化的检测
Exp Ther Med. 2024 May 22;28(1):294. doi: 10.3892/etm.2024.12583. eCollection 2024 Jul.

本文引用的文献

1
[Results of EGFR Mutations Detected in Pleural Effusion and Its 
Clinical Significance in 132 Patients with Advanced Non-small Cell Lung Cancer: 
A Retrospective Study in A Single Center].[132例晚期非小细胞肺癌患者胸腔积液中表皮生长因子受体突变检测结果及其临床意义:单中心回顾性研究]
Zhongguo Fei Ai Za Zhi. 2020 Dec 20;23(12):1059-1065. doi: 10.3779/j.issn.1009-3419.2020.104.23.
2
Retrospect and Prospect for Lung Cancer in China: Clinical Advances of Immune Checkpoint Inhibitors.中国肺癌的回顾与展望:免疫检查点抑制剂的临床进展。
Oncologist. 2019 Feb;24(Suppl 1):S21-S30. doi: 10.1634/theoncologist.2019-IO-S1-s02.
3
Cancer statistics, 2018.癌症统计数据,2018 年。
CA Cancer J Clin. 2018 Jan;68(1):7-30. doi: 10.3322/caac.21442. Epub 2018 Jan 4.
4
Improved detection of EGFR mutations in the tumor cells enriched from the malignant pleural effusion of non-small cell lung cancer patient.非小细胞肺癌患者恶性胸腔积液中富集的肿瘤细胞中表皮生长因子受体(EGFR)突变检测的改进
Gene. 2018 Feb 20;644:87-92. doi: 10.1016/j.gene.2017.10.073. Epub 2017 Oct 31.
5
The value of cell block based on fine needle aspiration for lung cancer diagnosis.基于细针穿刺的细胞块在肺癌诊断中的价值。
J Thorac Dis. 2017 Aug;9(8):2375-2382. doi: 10.21037/jtd.2017.07.91.
6
, , , and alterations in never-smokers with non-small cell lung cancer.从不吸烟者非小细胞肺癌中的……、……、……和改变。(原文内容不完整,有部分缺失信息,翻译可能不太准确)
Oncol Lett. 2016 Apr;11(4):2371-2378. doi: 10.3892/ol.2016.4235. Epub 2016 Feb 17.
7
[Consensus on epidermal growth factor receptor gene mutation detection in non-small cell lung carcinoma].非小细胞肺癌表皮生长因子受体基因突变检测的共识
Zhonghua Bing Li Xue Za Zhi. 2016 Apr 8;45(4):217-20. doi: 10.3760/cma.j.issn.0529-5807.2016.04.001.
8
Clinical features and survival of lung cancer patients with pleural effusions.伴有胸腔积液的肺癌患者的临床特征与生存情况
Respirology. 2015 May;20(4):654-9. doi: 10.1111/resp.12496. Epub 2015 Feb 23.
9
Sample features associated with success rates in population-based EGFR mutation testing.基于人群的 EGFR 突变检测成功率相关的样本特征。
J Thorac Oncol. 2014 Jul;9(7):947-956. doi: 10.1097/JTO.0000000000000196.
10
Transcription expression and clinical significance of dishevelled-3 mRNA and δ-catenin mRNA in pleural effusions from patients with lung cancer.肺癌患者胸腔积液中Dishevelled-3 mRNA和δ-连环蛋白mRNA的转录表达及临床意义
Clin Dev Immunol. 2012;2012:904946. doi: 10.1155/2012/904946. Epub 2012 Feb 23.